Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 1997

View Archived Issues

Antibacterial agent isolated by Sanwa Kagaku

Green Cross claims hypolipidemic agents

Anthracyclines from Microbial Chemistry Research Foundation

Cell adhesion inhibitors disclosed by Nippon Shinyaku

New antibacterial agents from Daiichi

Bayer claims potassium channel modulators

Activated immunoglobulins reported by Nippon Zoki

AutoImmune reports 1996 fourth-quarter and year-end financial results

Chiroscience Group 1996/7 pharmaceutical development update

Genzyme Tissue Repair reports 1996 results

ICN reports record sales, net income and EPS for 1996 and fourth quarter

ViroPharma reports 1996 financial results

Salix completes filing for ulcerative colitis treatment

Nymox and MGH collaborate on gene therapy

John Wayne Cancer Institute initiates first clinical trials on Pseudomonas exotoxin

Array Medical's Actalyke system receives FDA approval

VIMRx and Columbia University create new gene research company

Pfizer initiates clinical trial in panic disorder

Genelabs Technologies and BMS reach agreement in Taiwan

Positive phase III results for GelTex's RenaGel

Genome Therapeutics and Versicor collaborate on new antibacterial compounds

Advanced-generation matrix HRT patch launched in U.K.

Pharmacyclic earns NCI support for anticancer compounds

Positive phase I results for new formulation of lexipafant

Zorac available in Germany

SKB's Vectavir introduced in Germany

German introduction for spirapril

Novo Nordisk and Dyax collaborate on drug discovery

First approval for naratriptan

GS-4104 enters human testing

U.S. patent for Sugen's lead cancer therapeutic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.